JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Larimar Therapeutics (NASDAQ:LRMR) and maintained a price target of $17.
August 15, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a 'Market Outperform' rating on Larimar Therapeutics and maintained a price target of $17.
The reiteration of a 'Market Outperform' rating by JMP Securities indicates a positive outlook for Larimar Therapeutics. The maintained price target of $17 suggests that the analyst believes the stock is undervalued at its current price, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100